Patient-specific quality assurance for IMRT by Neeley, Michelle Lynn
University of Tennessee, Knoxville 
TRACE: Tennessee Research and Creative 
Exchange 
Masters Theses Graduate School 
5-2009 
Patient-specific quality assurance for IMRT 
Michelle Lynn Neeley 
University of Tennessee 
Follow this and additional works at: https://trace.tennessee.edu/utk_gradthes 
Recommended Citation 
Neeley, Michelle Lynn, "Patient-specific quality assurance for IMRT. " Master's Thesis, University of 
Tennessee, 2009. 
https://trace.tennessee.edu/utk_gradthes/5741 
This Thesis is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and 
Creative Exchange. It has been accepted for inclusion in Masters Theses by an authorized administrator of TRACE: 
Tennessee Research and Creative Exchange. For more information, please contact trace@utk.edu. 
To the Graduate Council: 
I am submitting herewith a thesis written by Michelle Lynn Neeley entitled "Patient-specific 
quality assurance for IMRT." I have examined the final electronic copy of this thesis for form and 
content and recommend that it be accepted in partial fulfillment of the requirements for the 
degree of Master of Science, with a major in Physics. 
Marianne Breinig, Major Professor 
We have read this thesis and recommend its acceptance: 
Accepted for the Council: 
Carolyn R. Hodges 
Vice Provost and Dean of the Graduate School 
(Original signatures are on file with official student records.) 
To the Graduate Council: 
 
I am submitting herewith a thesis written by Michelle Lynn Neeley entitled “Patient-
Specific Quality Assurance for IMRT.” I have examined the final electronic copy of this 
thesis for form and content and recommend that it be accepted in partial fulfillment of 
the requirements for the degree of Master of Science, with a major in Physics. 
      
                                      
Marianne Breinig 
 Major Professor 
 
 
We have read this thesis 
and recommend its acceptance: 
 
    
Chester Ramsey 
 
    
Katherine Grzywacz Jones 
 
       
      Accepted for the Council: 
       
Carolyn R. Hodges 
Vice Provost and Dean of the Graduate School 
 
 
(Original signatures are on file with official student records.)
Patient-Specific Quality  










A Thesis Presented for 
the Master of Science Degree 































Copyright © 2009 by Michelle Lynn Neeley 



















I would like to thank everyone who contributed to my learning at the Thompson 
Cancer Survival Center and especially to Dr. Chester Ramsey.  With out his 
guidance, encouragement, and creative thought, the following studies would 





In radiation therapy, QA is an integral part of the IMRT treatment process. 
This study evaluated two different QA modalities, a heterogeneous RANDO 
phantom and the MatriXX Detector.  The RANDO phantom study evaluated the 
dosimetric accuracy of a helical TomoTherapy system which resulted in a 
benchmark being established for dosimetric accuracy in heterogeneous 
materials.  The MatriXX study evaluated the performance of the MatriXX Detector 
to determine if it could be used as a substitute for radiographic film in rotational 
IMRT delivery techniques.  At least twenty test cases were selected for each 
study, and treatment plans were created using the Hi-Art TomoTherapy 
treatment planning and delivery system.  Kodak EDR2 radiographic films were 
used and processed in batches of five films at least one hour after irradiation.  
Horizontal profiles, vertical profiles, and Gamma pass/fail plots were calculated 
for each test case.  For the Gamma calculations, the threshold parameters were 
set to a 3% dose difference and a 3-mm distance-to-agreement.   
Analysis of the gamma pass/fail plots for the RANDO phantom study 
showed the lung cases had 27.2% of the pixels exceeding gamma, while the 
prostate patients had 14.7%.  For the prostate test cases, only two of the films 
had greater than 20% of the pixels exceeding the gamma threshold, while only 
four of the lung test cases were below the 20% pixel threshold.  Analysis of the 
gamma pass/fail plots from the MatriXX study showed the percent of pixels 
exceeding gamma was 10.8 ± 6.7% for the film verses 23.4 ± 13.8% for the 
 
 v 
MatriXX detector. The MatriXX appears to function well in high-dose low-gradient 
regions and low-dose low-gradient regions.  However, the MatriXX has difficulty 
in regions with steep dose gradients due to volume averaging across the ion 
chambers, and the coarse 7.62 mm center-to-center spacing of the chambers.  
The RANDO phantom study analysis revealed that discrepancies between 
calculated and measured dose distributions occurred at tissue-bone interfaces.  
Further investigation will be needed to determine if these errors are due to film 
response at heterogeneous tissue interfaces or from actual dose calculation 








This work is divided into six chapters.  The first three chapters provide an 
introduction to medical physics and radiation therapy, the clinical accelerators 
used in this study, and the need for quality assurance and the modalities used.  
The last three chapters cover the study set-up, results, and conclusion.  Figures 
corresponding to the study are found in Appendix I and tables in Appendix II.  
Portions of this work were taken from supporting documents submitted to the 
50th annual American Association of Physicists in Medicine meeting (AAPM).  
Those documents were a collaboration between Dr. Chester Ramsey and me.  
The RANDO phantom study was presented at the 50th annual AAPM meeting.  
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1.1 Medical Physics and Radiation Therapy 
The primary use of radiation therapy is to eliminate cancerous cell 
populations.  These cell populations are identified through an imaging modality 
such as computed tomography (CT) or positron emission tomography (PET).  
Once identified, these cell populations are exposed to fields of ionizing radiation 
which damage the cells’ DNA eventually causing cell death.  Ionizing radiation 
can be delivered using a clinical linear accelerator or using radioactive materials.  
Brachytherapy is a form of cancer treatment that uses small radioisotopes placed 
inside a body cavity delivering gamma rays to the surrounding tissue.  The most 
common form of radiation delivery is through the use of a linear accelerator or 
linac.  Linacs deliver external beam radiation therapy by utilizing ionizing 
radiation to penetrate a cancerous cell population and deliver a prescribed dose.  
The prescribed dose is achieved in multiple fractions using a beam that is 
shaped and delivered from multiple angles sparing as much healthy surrounding 
tissue as possible.  
Medical physics is an applied branch of physics that is concerned with the 
safe delivery of radiation in order to achieve a therapeutic effect.  As a patient 
progresses through the cancer treatment process, many people play an active 
role.  The medical physicist’s role is to ensure radiation safety, help to develop 
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new therapeutic techniques, collaborate with the radiation oncologists to design 
treatment plans, and to monitor equipment and patient procedures through 
quality assurance [1].   
 
1.2 Biological Effects of Radiation 
When external beam radiation is chosen as the cancer treatment modality, 
it is delivered using a linac.  Both electrons and photons are used in cancer 
treatment and are forms of ionizing radiation.  Electrons are directly ionizing due 
to the fact that they have enough kinetic energy to produce ionizing effects 
through collisions as they penetrate through matter.  This is better known as the 
bremsstrahlung process.  The electron interactions are provoked by the Coulomb 
force between the electric field of the penetrating electron and the electric fields 
of the orbital electrons and nuclei of atoms in the material.  In radiation therapy, 
electron energies range from 6MeV (mega-electron volts) up to 20MeV.   
Photons are an indirect form of ionizing radiation.  They liberate directly 
ionizing particles, such as electrons, from matter during their interactions.    
When photons are used in radiation therapy, their ionization ability is dominated 
by the Compton process [2].  In the Compton process, the initial photon interacts 
with a free electron in matter (an electron whose binding energy is very small 
compared to the energy of the initial photon) transferring part or all of its energy 
creating a fast electron.  The fast electron then directly ionizes the surrounding 
matter.  If the initial photon didn’t transfer all of its energy, it will continue on a 
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deflected path repeating the Compton process until it transfers all of its energy.  
The fast electrons produced are able to ionize other atoms of the material, break 
vital chemical bonds, and ultimately lead to the chain of events known as 
biological damage [2].   
The biologic effects of the x-rays can be a result of a direct action from the 
fast electrons or an indirect action.  A direct action is when the fast electron or 
recoil electron directly ionizes the target molecule.  An indirect action is when the 
fast electrons interact with another molecule, such as water, to produce a radical 
which interacts with the target molecule causing damage.  The majority of 
damage from x-rays is caused by indirect action to the target molecule’s DNA.  In 






2.1 Basic Components 
The prescribed dose of radiation is delivered using a linac.  Linacs use 
high-frequency electromagnetic waves to accelerate charged particles, such as 
electrons, to high energies through a linear accelerating tube.  The high-energy 
electron beam can be used for treating superficial tumors, or it can be made to 
strike a target producing x-rays for treating deep-seated tumors [3, 4].  A linac 
has two main parts, a stand and the gantry.  These two parts house all the 
necessary internal components for operation.  All linacs have the same basic 
internal components.  The components found in the stand are a cooling water 
system, power supply, modulator, klystron/magnetron, waveguide, and circulator.  
The electron gun, accelerating structure, and bending magnet are found in the 
gantry.  These components are shown in Figures 1 and 2.  All figures are found 
in Appendix I.  
The cooling water system is a necessary element found in the base of the 
stand which has two functions.  First, it cools parts of the accelerator that 
dissipate energy as heat, and secondly, it keeps the accelerator at a stable 
operating temperature that is above room temperature in order to avoid 
condensation from forming inside the accelerator.  The power supply provides 
direct (DC) power to the modulator, which produces high-voltage, flat-toped DC 
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pulses that are microseconds in duration.  These pulses are sent simultaneously 
to the electron gun and the magnetron/klystron.  The klystron/magnetron uses 
the high-voltage DC pulses to produce pulsed microwaves which are carried via 
the waveguide to the accelerating structure.  Klystrons are used in high-energy 
accelerators due to the fact that they can deliver higher power levels which are 
required as the beam energy reaches greater than 12MV.   
Although it may be more expensive, most linacs contain circulators.  This 
is a device that is inserted into the waveguide to stop microwaves from being 
reflected back into the klystron/magnetron via the waveguide.  If reflected 
microwaves were able to reach the klystron, it would damage or detune the 
structure resulting in the inability to produce microwaves.  The electron gun is 
located at the end of the accelerating structure near the waveguide.  The electron 
gun is a simple cathode that injects electrons into the accelerating structure.  
These electrons are energized by the pulsed microwaves from the 
klystron/magnetron.  In the accelerating structure, the electrons are sent through 
a linear series of cavities.   
Most accelerating structures in present-day linacs are standing wave 
accelerators due to the fact that they are much shorter than traveling wave 
accelerating structures.  The electric wave in a standing wave accelerator varies 
in magnitude with time in a sinusoidal pattern, but remains stationary along the 
axis (not advancing).  This can be visualized by imaging a string fixed at both 
ends, but oscillating up and down.  As the electric field oscillates, the electrons 
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are accelerated forward through the structure.  With every pulsed microwave, a 
new group of electrons are accelerated down the structure resulting in incident 
and reflected waves.  These incident and reflected waves combine to produce 
standing waves that oscillate back and forth approximately one hundred times 
during a five microsecond pulse [3].  The resulting standing waves have 
stationary nodes that are located within every other cavity of the accelerating 
structure and contain no electric field.  Because there is no electric field in the 
nodal cavities, they do not contribute to the acceleration of the electrons.  These 
cavities can therefore be moved off axis and shortened due to the fact that the 
resonance of a cavity is not based on length, but diameter.  This results in 
shortening of the whole structure.  After the electrons pass through the 
accelerating structure, they are sent into the bending magnet which deflects the 
electrons into a 270o loop focusing the electron beam. 
 
2.2 The Gantry Head 
The gantry head is a very important component of the linac.  This is where 
beam shaping, localizing, and monitoring take place [3].  The gantry head not 
only contains the bending magnet, but the retractable x-ray target, flattening filter, 
scattering foils, ionization chambers, and the collimators (primary and secondary) 
as seen in figures 3 and 4.  The retractable x-ray target is a thin, high Z material, 
such as tungsten, that produces photons when bombarded with electrons.  The 
resulting photon beam is forward peaked meaning that the greatest intensity of 
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photons are near the beam’s central axis and less intense elsewhere.  To correct 
the forward peaked beam, a very thin, conical metal absorber is placed in front of 
the beam.  This allows for absorption of photons from the more intense region of 
the central axis resulting in a uniform dose distribution across the beam.   
In electron therapy, the x-ray target and flattening filter are retracted and 
the scattering foil is inserted into the path of the electron beam.  The scattering 
foil spreads out the focused beam coming from the bending magnet (figure 5).  
The scattering foil is only used for electron therapy.  As figure 5 shows, there is a 
set of ion chambers that sit below the carousel for the flattening filter and 
scattering foil.  This set of ion chambers samples the radiation beam (photons or 
electrons) as it passes through the head of the gantry.  These ion chambers send 
a signal back to the treatment control station reporting how much dose has been 
delivered, and terminates the treatment when the prescribed dose has been 
achieved.  The purpose for having two ion chambers is simply to have two 
independent measurements using one measurement to check the other.   
The last important component of the gantry head is the primary and 
secondary collimators.  As seen in figures 4 and 5, the primary collimator sits just 
below the x-ray target and initially shapes the photon beam, where as the 
electron beam is still focused and passes through to the scattering foil.  The 
secondary collimator is a set of four, thick tungsten blocks that move in pairs.  
These pairs are called jaws, and they help create sharp edges on all sides of the 
electron or photon beam.  These sharp beam edges are necessary to minimize 
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penumbra.  Penumbra is the region at the edge of the radiation beam where 
dose changes rapidly as a function of distance from the beam axis.  The jaws 
can create field sizes up to 40 x 40 cm at a distance of 1 meter from the target.    
A special case of collimation for treatment fields that are not rectangular in 
shape is the use of a multileaf collimator (MLC) (figure 6).  The MLC is built into 
the gantry head and is found below the secondary collimator.  It is the last 
component that the beam passes through before entering the patient.  The MLC 
is typically made up of 80 (40 pairs) collimating blocks or leaves that are 
independently motor driven to produce a field of any shape or size up to 40cm x 
40cm.  Each MLC is made out of tungsten, and collectively they have a leaf 
thickness sufficient enough to block 98% of the photon beam at any given 
position [4].  This allows for a more conformal treatment area that targets the 
tumor volume and spares healthy surrounding tissue.   
 
2.3 Varian Clinac 2100 EX 
The Thompson Cancer Survival Center (TCSC) has two clinical linear 
accelerators, one of which being a Varian Clinac 2100 EX (Varian Medical 
Systems, Palo Alto, CA) and the other a HI-ART TomoTherapy linac 
(TomoTherapy, Inc., Madison, WI).  The Varian 21EX is the most prevalent type 
of linac used in cancer treatment.  The linac consists of the stand and gantry 
which both house the same basic components and design as mentioned above.  
In this machine, the standing waveguide is used in conjunction with a triode 
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electron gun.  A triode gun uses an additional grid to control the electron beam 
current, which is normally held negative to the cathode, in order to cut off the 
current to the anode.  By using this design, the additional grid is able to control 
the timing and magnitude of the current pulses injected into the accelerating 
structure. 
The Varian 21EX is klystron driven with allowable photon energies of 6 
MV and 18 MV, and allowable electron energies ranging from 6 MeV to 20 MeV.  
The linac has the capability of delivering dose from 100 to 600 MU/min to field 
sizes ranging from as small as 0.5 cm2 up to 40.0 cm2.  The Varian 21EX 
employs a 120-tungsten leaf MLC consisting of fifteen 1cm thick leaves at the top 
and bottom of the MLC carriage and thirty 0.5 cm thick leaves in the middle of the 
MLC allowing for greater conformity around the target.  The Varian 21EX has 
image guidance capabilities referred to as PortalVision.  Portal Vision is a 
megavoltage imaging system used to ensure treatment plan verification, accurate 
patient setup, and effective treatment delivery.  PortalVision takes low energy x-
rays allowing clinicians to ensure the patient is properly set-up and the target 
volume is in the treatment area [5].  
The Varian 21EX employs a hydraulic treatment couch that is capable of 
withstanding 300+ pounds and moves vertically and horizontally for patient 
positioning.   The Varian 21EX at TCSC was manufactured so that its isocenter is 
located at 100 cm from the target source in the gantry head.  The machine’s 
isocenter is the imaginary intersection point in space of the axis of rotation of the 
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collimator and the axis of rotation of the gantry.  Patients are typically set up 




Besides traditional linear accelerators, there is Tomotherapy (figure 7).   
Tomotherapy is a linear accelerator with CT capability that is designed to deliver 
a more conformal dose distribution for Intensity Modulated Radiation Therapy 
(IMRT) treatments.  The machine’s design is based largely on the concept of a 
CT scanner.  Internally, Tomotherapy geometrically employs a ring gantry design 
with a binary multi-leaf collimator which rotates simultaneously with the couch’s 
linear motion into the gantry bore.  This results in delivery of a continuous, helical 
(360o) dose pattern around the patient (Figure 8).   
Tomotherapy contains all the major components of a traditional linear 
accelerator and are arranged to fit inside the doughnut-like shape of the 
machine.  Tomotherapy employs a 3GHz magnetron to produce pulsed 
microwaves instead of a klystron due to the low energy needed for treatment.  A 
6MV linear accelerator is mounted on the ring gantry which delivers an IMRT 
treatment plan specific to each patient.  Opposite the treatment head is a 13cm 
thick lead counter weight attached to the gantry that acts as a rotating beam 
stopper.  Tomotherapy’s binary MLC consists of 64 tungsten leaves that are 
individually 10cm high.   
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The MLC defines the treatment field as a narrow open slit creating a wide 
fan beam in the axial direction.  The maximum width of the projected beam to the 
axis is 40 cm, thus defining the maximum width for any patient treatment field as 
40 cm.  During treatment, the MLC leaves are either open or closed, and each 
leaf moves independently to modulate and shape the beam as the gantry moves 
around the patient.  As the gantry rotates, Tomotherapy’s couch is designed to 
move the patient at a constant velocity into the gantry bore and a maximum of 
160 cm during the course of treatment.  This defines the maximum length of any 
patient treatment field to be 160 cm.  Because Tomotherapy’s couch is designed 
to move during treatment, a larger volume can be treated in one set-up.   
The fan beam design of Tomotherapy allows radiation to be delivered in a 
slice-by-slice manner.  Tumor volumes are subdivided into a stack of slices that 
are independently irradiated and collectively result in a 3D conformal dose 
distribution.  Tomotherapy employs 51 beams spaced roughly seven degrees 
apart creating a continuous treatment field [6, 7].  Because of Tomotherapy’s 
dynamic nature, it is critical that the couch, gantry, and MLC leaves are all in 
sync.  
Tomotherapy is an example of Image-Guided Radiation Therapy (IGRT).  
The linac is designed with a built-in CT scanner which provides image guidance 
in the treatment room.  MVCT (megavoltage CT) imaging is performed prior to 
each treatment to ensure the patient is correctly placed on the treatment couch, 
and to confirm the tumor volume resides within the volume to be treated.  The 
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resulting MVCT images are fused and registered with the planning CT images at 
the treatment console to determine if the patient needs to be repositioned for 
treatment.  Tomotherapy’s couch automatically adjusts the patient vertically and 
longitudinally to account for roll.   To account for yaw and pitch, patient 
immobilization and positioning devices are used during treatment.  The use of 
IGRT before treatment has helped to identify the exact 3D location of tumor 





In static external beam photon radiation therapy treatments, the photon 
beam has a uniform intensity across the field.  Because of this, a simple hand 
calculation can be performed independent of the planning station to verify the 
dose being delivered to the patient and the planning station dose are in 
agreement.  With recent technological advances, linear accelerators have the 
ability to deliver IMRT treatments.  IMRT treatments do not have a uniform 
intensity across the field.  Instead, the intensity is modulated by the MLC and 
delivered from a multitude of beam angles to make an optimal composite dose 
distribution.   
Because the field is not uniform, a hand calculation is impossible to 
perform, and therefore, the dose must be verified using another modality.  A 
protocol for patient-specific quality assurance (QA) was developed to solve this 
problem and has become a major component of the IMRT clinical process [8].  
The objective of this often time-intensive measurement process is to verify that 
the prescribed dose is accurately being delivered to the target volume (tumor) 
while sparing the healthy surrounding tissue.  This study investigates two 
different modalities for IMRT QA, evaluates the dosimetric accuracy of both a 
helical tomotherapy system and Varian linac system, and investigates the 
benefits of constant dose rate (CDR) VMAT delivery techniques.   
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3.1 IMRT Treatments 
The main objective of IMRT is to treat patients from a number of different 
angles with non-uniform intensity beams that have been optimized to deliver a 
high dose to the tumor and a very low dose to healthy surrounding tissue and 
critical structures.  IMRT is a radiation delivery technique that uses inverse 
planning software to “shape” or conform a photon beam using a computer 
controlled MLC.  The MLCs are employed as compensators to modify the 
intensity profile by moving in and out of the beam’s path in order to meet the 
goals of a composite plan.  This non-uniform fluence can be delivered to the 
patient from any angle.   
As with any radiotherapy plan, a 3D CT data set is needed, along with 
image registration, critical structure contours, and beam selection and placement.  
For IMRT, the planning software must have the ability to create beam segments 
and contain an IMRT optimization algorithm.  The user enters the dose criteria for 
the target (tumor) and critical structures.    The software then optimizes the 
intensity profiles for each beam and calculates the composite dose distribution.  
After the generation of an acceptable IMRT plan, the intensity profiles for each 
beam are electronically transferred to the linear accelerator’s delivery system [4].  
There are three types of static IMRT delivery techniques, step-and-shoot, 
sliding window, and intensity modulated arc therapy (IMAT).  Of these three 
techniques, step-and-shoot is the most widely used delivery technique, and the 
technique used in this study.  In the step-and-shoot delivery technique, the 
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patient is treated with multiple beams that are individually subdivided into a 
series of segments or different shapes.  These segments are created by the 
planning software, shaped using the MLC, and are delivered successively 
without operator intervention.  Each beam segment produces a unique intensity 
profile, modulating the beam from segment to segment.  After the completion of 
all segments for one beam angle, the operator must move the gantry to the next 
beam angle where the process repeats itself.  The accelerator’s beam is not 
turned on during MLC movement or gantry rotation resulting in its name, step-
and-shoot IMRT.  A subfield of step-and-shoot IMRT is dynamic-step-and-shoot.  
In this method the accelerator’s beam is turned on throughout the delivery, even 
when the MLC leaves are moving.  Tomotherapy employs this method of step-
and-shoot IMRT. 
IMAT takes the idea of dynamic step-and-shoot IMRT one step further.  
IMAT uses multiple beam angles to create a 360o arc treatment in the linac’s arc 
therapy mode.  As in dynamic step-and-shoot, each field (arc) is divided into 
subfields of uniform intensity that collectively result in the desired intensity 
modulation.  The MLCs are constantly moving and shaping the beam as the 
gantry rotates, while the accelerator’s beam stays turned on throughout the 
treatment.  One MLC subfield is delivered per gantry angle resulting in multiple 
overlapping fields.  The number of gantry angles is determined by the gantry 
spacing set between each angle.  The IMAT treatment planning algorithm divides 
the two-dimensional intensity distribution created by inverse planning into 
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multiple one-dimensional intensity profiles.  These one-dimensional profiles are 
then decomposed into discrete intensity levels that are to be delivered by the 
subfields in a stack arrangement.  The super imposed subfields create the 
intensity modulation at each gantry angle [9]. 
 
3.2 VMAT Treatments  
IMRT does deliver more conformal dose distributions while sparing 
healthy surrounding tissue at the expense of longer treatment delivery times, 
multiple beam angles, and increased monitor units (MU).  In radiation therapy, a 
monitor unit (MU) is a measure of machine output for a linear accelerator.  Linear 
accelerators are calibrated for a specific energy such that 1 MU gives an 
absorbed dose of 1 centigray (cGy) at a depth of Dmax (or maximum dose) for a 
field size of 10x10 cm2 for a source-to-axis (SAD) distance of 100 cm.  
In an attempt to increase treatment efficiency, Volume Modulated Arc 
Therapy (VMAT) was developed.  VMAT is a special type of IMRT in which 
radiation is delivered in single or multiple gantry rotations using a dynamic MLC 
and modulated gantry speeds.  There are two types of VMAT, constant dose rate 
(CDR) and variable dose rate (VDR).  CDR VMAT is when the dose rate is set at 
one specific rate throughout the treatment delivery.  For example, the dose rate 
could be set to 300MU/min.  VDR VMAT is when the dose rate changes 
throughout the treatment delivery.  In VDR, the dose rate could be programmed 
to begin with 400 MU/min, then change to 200 MU/min at a specific gantry angle 
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partially through the treatment, and end with 600 MU/min.  The main objective of 
VMAT is to deliver a treatment that is just as conformal, if not better, than a step-
and-shoot IMRT treatment and hopefully, in less time.  Before the invention of 
VMAT, Tomotherapy was the only efficient arc treatment technique available.  
With improvements in recent technology, conventional linacs will have the ability 
to deliver 360o arc treatments with the instillation of the appropriate software 
upgrades [10, 11].   
 
3.3 Devices Used 
In order to perform patient specific QA, the composite IMRT dose 
distributions must be measured.  Measurement of the dose distributions can be 
achieved using a wide variety of techniques and devices known as dosimeters.  
Some such devices include film (radiographic and radiochromic), ion chamber 
arrays (MatriXX Detector), diode arrays, and Electronic Portal Imaging Devices 
(EPIDs).  Composite dose distributions are obtained by irradiating a test phantom 
containing dosimeter(s).   
 
3.3.1 Phantoms, Film, and Ion Chambers 
Of all the available modalities, film is still one of the most versatile and 
most frequently utilized measurement systems.  When film is utilized as the 
dosimeter, it is placed in a coronal, sagittal, or transverse plane inside a phantom 
(figure 9).  Because the film is irradiated using the same delivery sequence used 
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to treat the patient, the dose given to specific anatomical structures (such as the 
parotids, spinal cord, bladder, rectum etc…) can be evaluated.  
Radiographic film and homogeneous solid water phantoms are commonly 
used in patient-specific quality assurance testing.  At TCSC Kodak radiographic 
EDR2 film is commonly used.  This type of film is used for doses delivered above 
100 cGy, but below 600 cGy and comes sealed in a light safe jacket.  
Radiographic film consists of three layers.  The first layer is a transparent film 
base made of polyester resin.  The middle or second layer is a double emulsion 
containing very small crystals of silver bromide which is topped by another 
transparent film base.  When the film is exposed to radiation (or visible light), the 
silver bromide crystals undergo a chemical change forming a latent image.  
When the film is developed, the crystals that have undergone a chemical change 
reduce to small grains of metallic silver.  As the film is fixed, the unaffected silver 
bromide crystals are dissolved by the fixing solution resulting in a clear film.  The 
metallic silver crystals are unaffected by the fixing solution resulting in a dark 
appearance, and thus a negative film results.  The intensity of darkening on a film 
depends on the amount of metallic silver created by the radiation energy 
absorbed [12]. 
The darkness of the film can be measured by determining the optical 
density or absorbance of the film using a densitometer.  A densitometer consists 
of a light source passing light through a diffusing screen incident on a small 
aperture.  The film being tested sits on top of the aperture.  The light transmitted 
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through the aperture and film is detected using a photocell.  The photocell 
collects all light coming through the aperture regardless of its direction.    The 
transmitted light is known as It.  The amount of light detected when no film is in 
place is known as Io.  The optical density is calculated by comparing these two 
values using, log(Io/It).  The optical density is affected by radiation exposure and 
development procedures.  To be a useful dosimeter, the film development must 
be carefully monitored to ensure the correct chemical(s), time, temperature, and 
agitation are taken into account.  For each type of film used, a calibration of 
density versus exposure should be performed [4, 12].  This will be discussed 
further in chapter 5.   
When using film as the dosimeter for patient specific QA, phantoms are 
used to simulate the patient.  There are primarily two types of phantoms, 
homogeneous or heterogeneous.  Homogeneous phantoms are made out of a 
material, referred to as solid water, which is the same density as human soft 
tissue.  Solid water can come in the form of square blocks of different 
thicknesses or in the shape of a cylinder with a specific thickness (figure 10).  
Regardless of which form of solid water is used, the film is placed between two 
pieces of the phantom in a coronal, saggital, or transverse plane.  Upon 
placement, the film is typically pricked with a pin to release any air bubbles in the 
film jacket and to create fiducial marks on the film.  There are very few 
heterogeneous phantoms used in patient specific QA.  One such phantom is the 
RANDO phantom.  This phantom simulates the different densities of bone, soft 
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tissue, and air cavities in the body.  These phantoms tend to be big, bulky, and 
heavy making QA set-up difficult and time consuming.  Due to the fact that the 
treatment planning stations take into account patient heterogeneities, and not 
much is known about the accuracy of heterogeneous phantoms, most institutions 
do not use them regularly. 
In conjunction with film and phantoms as QA modalities, ionization 
chambers are frequently used to measure absorbed dose at a specific point in 
the treatment volume.  The ionization chamber is placed inside the phantom and 
connected to an electrometer where the charge collection is displayed in 
nanocoulombs.  After irradiation, the ionization reading can then be converted 
into dose using equation 1.  
                                   
(1)
              
DQw is the absorbed dose to water at the point of measurement of the ion 
chamber placed under reference conditions, M is the fully corrected ion chamber 
reading, kQ is the quality conversion factor which converts the calibration factor 
for a 60Co beam to that for a beam of quality Q, and N60CoD,W is the ion chamber 
absorbed-dose-to-water calibration factor [4, 12, 13].  
There are many different types of ionization chambers, but the most 
widely used for patient specific IMRT QA are thimble chambers.  A basic 
ionization chamber is an enclosure containing two or more electrodes in which an 
electric current is passed when the enclosed gas is ionized by radiation.  
Specifically for this study, the gas used in thimble chambers is air and is ionized 
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using a photon beam.  The design of thimble chambers takes on the look of a 
sewing thimble (figure 11).  A low atomic numbered material is used for the walls, 
which are typically 5 mm thick,  in order to have the same effective number as 
atmospheric air.  Because of this, the materials of the wall and electrodes 
produce ionization essentially similar to that produced in a free-air ionization 
chamber.  The inside of the solid chamber wall is made into an electrode by the 
application of a special material (graphite, Bakelite, or plastic coated graphite and 
Bakelite) to make it electrically conducting.  The second electrode is a rod of low 
atomic number material (graphite or aluminum) that is held at the center of the 
thimble, but electrically insulated from it.  In order to collect the ions produced 
from irradiation of the chamber, a voltage is applied between the two electrodes.  
Ion chambers do require periodic calibration [4, 12].  
 
3.3.2 MatriXX Detector 
Radiation therapy patients that are treated with Intensity Modulated 
Radiation Therapy (IMRT) and Volume Modulated Arc Therapy (VMAT) must 
have their calculated dose distributions verified with calculations and/or 
measurements as stated earlier.  In the past, radiographic film has typically been 
used to measure and verify IMRT dose distributions as part of the quality 
assurance process.  Many radiation therapy departments have transitioned to 
digital imaging systems, and the medical physicist(s) may no longer have access 
to chemical-based “wet” film processors.  As a result, there are now a variety of 
 
 22 
new media and devices that could potentially be used as a substitute for 
radiographic film.  One such device is the IBA MatriXX Detector (IBA Dosimetry 
America, Bartlett, TN) (figure 12).  The MatriXX is a vented ionization chamber 
array with 1020 separate 4.5 x 5 mm2 ion chambers.  Each chamber has a 
volume of 0.08 cm3, and the detectors are spaced 7.62-mm center to center.  
The chambers are arranged in a 32 x 32 grid with an active area of 24.4 cm2.  
The device itself has 3.3-mm of water equivalent material on the top surface, and 
22-mm of backscatter material on the bottom.  The MatriXX detector comes with 
its own software that has analysis capabilities, but it was not used for the 








In the discussion of the following studies regarding patient specific QA for 
IMRT, specific clinical set-ups were used and will now be described. 
 
4.1 Rando Phantom 
Heterogeneous phantoms that simulate the different tissue densities in the 
human body do exist, but are infrequently used for patient-specific IMRT QA.   
The potential advantage of using heterogeneous phantoms is that the measured 
dose distributions will more adequately reflect the clinical dose distributions in the 
patients.  The use of homogenous phantoms during IMRT quality assurance can 
potentially mask errors that arise from limitations in the treatment planning 
system’s modeling of density corrections.  This study evaluated the dosimetric 
accuracy of a helical tomotherapy system using an anthropomorphic RANDO 
phantom for patient-specific QA.  The results of this study allowed a benchmark 
to be established for dosimetric accuracy in heterogeneous materials.   
Patient-specific IMRT dosimetric verification was performed for twenty-four 
patients using a male Alderson RANDO Phantom (The Phantom Laboratory, 
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Salem, NY) (figure 13). The complete male RANDO phantom represents a 5’ 9”, 
163 lb human male and is separated transversely into 2.5-cm slices.  Each slice 
consists of a natural human skeleton cast inside a material that is radiologically 
equivalent to human soft tissue.  The soft tissue simulates human muscle tissue 
with randomly distributed fat.  The lung portion of the phantom is made with a 
lower density material simulating human lungs in a median respiratory state 
molded to naturally fill the rib cage (figure14) [15].  For this study, the phantom 
was divided into two separate sections:  1.) A lung phantom consisting of slices 
14 through 19; and 2.) A pelvic phantom consisting of slices 26 through 35.  The 
setup of both phantom sections is shown in Figure 15.   
In order to use the RANDO phantom for QA purposes, images of the 
phantom needed to be imported into the treatment planning station.  This was 
done via a CT scan of each phantom (lung and pelvic).  During “CT Simulation,” 
the RANDO lung and pelvic sections were each placed in Vac-Lok cushions 
(CIVCO, Orange City, IA) in order to hold the phantom sections together and to 
help ensure a reproducible set-up for QA delivery.  Vac-Lok cushions are 
inflatable bags that are filled with small Styrofoam balls.  Once inflated, patients 
are typically placed on top of the bags in their specific treatment position.  As the 
bag is deflated, it can be molded around the patient creating an outline of their 
shape and position.  Vac-Lok cushions can also be used for phantoms, as in this 
case.  Rigid molds of each phantom set-up were created and used for each of 
the patient-specific IMRT measurements.    
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In order to perform patient specific QA, QA treatment plans have to be 
created for each patient within the treatment planning station.  This is 
accomplished by using the QA tools on the planning station to overlay the 
patient’s optimized IMRT dose distribution onto a section of phantom and 
determine where the film should be placed if used as the dosimeter.  The 
treatment planning station takes into account the difference in densities between 
the patient and the phantom and adjusts the dose distribution accordingly.  If an 
ionization chamber is going to be used, the treatment planning station can 
calculate dose specifically for the location of the chamber in the phantom in order 
to compare the calculated dose with the measured dose obtained from the 
electrometer reading. 
For the RANDO phantom study, treatment plans were created for 12 
prostate and 12 lung patients using the Hi-Art TomoTherapy treatment planning 
and delivery system.  For the lung cases, the gross tumor volume or clinical 
target volume (CTV) consisted of the primary tumor volume as visualized on CT 
or PET/CT.  For the prostate test cases, the prostate CTV included the prostate 
gland and seminal vesicles.  IMRT QA plans were created for each patient using 
the corresponding phantom section (lung or pelvis), and the QA plans were 
designed so the tumor volume from the patient resided in the same anatomical 
site inside the RANDO phantom.    
To deliver the planned QA procedure, the corresponding phantom section 
was placed on the tomotherapy high-performance couch in the Vac-Lok cushion.  
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For the prostate test cases, an A1SL thimble ionization chamber (Standard 
Imaging, Middleton, WI) was placed in the phantom in the center of the target 
volume.  Ionization chamber readings were not taken for the lung cases due to 
the random location of the tumor site within the lung.  Kodak radiographic EDR2 
film was placed in a transverse plane between two of the phantom slices for both 
the prostate and lung cases.  The film was taped to the inside surface of the 
phantom to prevent film movement, and marked in three locations relative to the 
machine isocenter (Figure 16).  The phantom was then compressed using a belt 
mechanism to eliminate gaps and air pockets between the phantom slices.   
Once the phantom was correctly placed on the treatment table using the 
wall mounted lasers and prior to irradiation, the phantom was imaged using 
Tomotherapy’s MVCT system.  The MVCT images were fused with the treatment 
planning CT images using a pixel-by-pixel mutual information image registration 
algorithm.  From the image registration, the phantom was automatically 
repositioned in the anterior-posterior, superior-inferior, and lateral directions by 
the high-performance couch.  In addition, the roll corrections were automatically 
implemented by adjusting the treatment start angle within the treatment delivery 
system.  Yaw and pitch corrections were applied manually by moving and then 
re-imaging the phantom until values of zero were obtained in the treatment 
delivery system.   
After applying all the set-up corrections and correcting for pitch and yaw, 
the QA procedure was ready to be delivered.  After irradiation, all EDR2 QA films 
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were processed at least one hour after exposure in batches of five films. The 
films were scanned using a Vidar 16 Dosimetry Pro (Vidar Systems, Herndon, 
VA) and analyzed using both the Tomotherapy IMRT QA software and the RIT 
dosimetry software (Radiological Imaging Technology, Colorado Springs, CO) 
(figure 17).  The calculated dose distribution obtained during the QA procedure 
planning and the measured dose distribution obtained from irradiating the film 
were registered with one another using a fiducial-based registration system with 
the marks placed on the film prior to irradiation.  In addition to the IMRT QA films, 
calibration films were also shot.  The calibration films were shot on the Varian 
21EX using a 13 segment step-and-shoot sequence (see chapter 5 for more 
information).   
 
4.2 MatriXX Detector 
The primary objective of this portion of the study was to determine if the 
MatriXX detector could be used as a substitute for radiographic film in rotational 
IMRT delivery techniques, such as Tomotherapy.  In order to be useful for these 
delivery techniques, the device must be angular independent in dose-response 
and be capable of measuring composite dose distributions created during 
rotation.  In order to evaluate its performance, the MatriXX and radiographic film 
measurements were taken using one Volume Modulated Arc Therapy (VMAT) 
and nineteen Helical Tomotherapy treatment deliveries.       
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Twenty random patients who were treated with helical tomotherapy during 
the Fall of 2007 were selected for this comparative analysis. The original clinical 
treatment plans were created and delivered using the TomoTherapy planning 
and delivery system (Version 3.1).  Treatment planning for the VMAT test case 
was performed using the Pinnacle treatment planning system (Version 8.0, 
Philips Medical Systems, Bothell, WA) and delivered on the Varian 21EX.  The 
VMAT treatment plan was created using Pinnacle’s Direct Machine Parameter 
Optimization (DMPO) algorithm and was modeled and optimized as 51 equally-
spaced fixed beams with one fixed MLC aperture per gantry angle.  The plan was 
modeled this way due to the fact that VMAT planning software had not been 
developed yet.   
The MatriXX detector was setup with a single 5 x 30 x 30-cm3 slab of 
water-equivalent material (Solid Water, GAMMEX, Middleton, WI) centered over 
the detector array to provide sufficient buildup during treatment delivery.  The 
device was positioned flat on the table top for coronal imaging with the 
electronics pointing toward the end of the couch in order to avoid the radiation 
field.  Just as in the RANDO phantom experiment, the detector array in the 
MatriXX was CT imaged.  A 50-cm field-of-view and a slice thickness of 2-mm 
were used as the imaging parameters. When the CT images were imported into 
the Tomotherapy treatment planning system, they were automatically down-
sampled to 256 x 256 pixels in order to decrease computational times.  As a 
result, the final pixel dimensions for the MatriXX after import was 2-mm3.  In order 
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to maintain consistency in the VMAT experiment, the down-sampled CT images 
of the MatriXX were also imported into Pinnacle and assigned as an IMRT 
phantom.  The Tomotherapy and VMAT quality assurance plans were created in 
the respective planning systems by copying the patient’s plan to the CT images 
of the MatriXX and re-computing the dose. 
Measurements were performed with the MatriXX in the same setup and 
configuration as in the CT phantom plan. The MatriXX was initially positioned on 
the treatment table using the wall mounted lasers in the treatment room.  For the 
Tomotherapy test cases, the MatriXX was MVCT imaged and repositioned for 
treatment using the same image-guidance technique as described in the RANDO 
phantom study excluding the pitch and yaw corrections.  In order to compare the 
MatriXX with radiographic film, Kodak EDR2 film was placed on the surface of 
the MatriXX under the 5-cm thick slab of solid water.  The position of the film 
relative to the machine isocenter was marked using a pin to prick the film jacket.  
The position of the MatriXX relative to the machine isocenter was determined 
relative to the center of the array.  The same film calibration sequence used in 
the RANDO phantom study was also used in this study.  All MatriXX QA films 
were processed at least one hour after exposure in batches of five films. The 
films were scanned using a Vidar 16 Dosimetry Pro and analyzed using the RIT 





Quality Assurance Analysis and Results 
 
5.1 RIT Software Analysis 
Because IMRT treatments are too complex for QA hand calculations, 
specific software is used in the IMRT QA analysis process.  Radiological Imaging 
Technology (RIT) is recognized as one of the leading companies in automated 
IMRT QA analysis software.  The RIT software has the ability to automatically 
calculate a variety of methods including gamma analysis, vertical and horizontal 
profiles, and addition and subtraction plots to analyze an IMRT treatment.  If 
radiographic film is used as the QA dosimeter, the RIT software requires several 
initial tasks before the QA analysis can be performed.  The software requires a 
film calibration curve, importation of the dose map from the treatment planning 
station (TPS), and registration between the film and the TPS dose map.   
 
5.1.1 Film Calibration Dose to Density Curve 
The film calibration curve is a calibration file created with in the RIT 
software using actual dose measurements taken on the linac to assign film pixel 
values a dose value.  Several centimeters of solid water, a parallel-plate 
ionization chamber, and film are placed on the couch of the linac and positioned 
at the machine’s isocenter.  Several centimeters of solid water are used to 
prevent backscatter of radiation which would result in a false ionization chamber 
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reading.  The film and ionization chamber are irradiated using a 13-step-and-
shoot dynamic MLC file.  This file is programmed to deliver 13 stripes of radiation 
with each consecutive strip delivering slightly less radiation.  The ionization 
chamber is centered in the first stripe to acquire its ionization reading.  Once the 
reading has been recorded, the chamber has to be physically moved to the next 
stripe in order to acquire the second stripe’s reading.  This results in running the 
dynamic MLC file 13 times to acquire ionization readings for all 13 stripes.  Film 
is only used the first time the MLC file is ran to prevent saturation.  Once the film 
is processed and scanned into the RIT software, the calibration curve can be 
created (figure 18).  Using the parallel dose calibration option within the software 
allows the optical density of the 13 stripes on the scanned film to be assigned a 
dose value which is obtained from the ionization readings. The readings are 
converted to dose using equation 1.  By creating this film calibration file and 
applying it to any film during the analysis process, the software is able to assign 
a dose value which corresponds to the film’s optical density.  Without this 
calibration file, the analysis software dose not know how to interpret the film’s 
optical density, and therefore IMRT analysis can not be performed.   
 
5.1.2 Film Registration 
When analyzing IMRT QA films in RIT, registration between the film and 
the TPS dose image must be performed in order to define a coordinate system 
corresponding to both images.  The TPS dose image is considered the 
 
 32 
calculated image, i.e. what the film or measured image should look like after 
irradiation.  The TPS dose image must be imported, and the irradiated film must 
be scanned into the RIT software.  Once the film has been scanned into the 
software, the film calibration curve needs to be applied in order to assign dose to 
the irradiated parts of the film.  Once the scanned film has been calibrated, the 
film and TPS dose image can be registered and analyzed.  Registration between 
the two is typically performed using a fiducial-based registration system.  Marks 
are placed on the film relative to the machine’s isocenter prior to being radiated 
using a pin to prick the film jacket.  This allows visible light through the light-safe 
film jacket in those areas causing saturation of the film.  
Once the film is developed these fiducial marks appear as white dots 
(Figure 16).  All films should be marked identically with respect to the machine’s 
isocenter.  By doing this, a coordinate-based template can be created in RIT.  
This template is then applied to both the film and TPS dose image during the 
registration process.  The application of the template defines the corresponding 
coordinate system that links the two images for IMRT QA analysis.  Registration 
can also be performed manually.  This entails the user randomly selecting 
corresponding points between the TPS dose image and the film.  This form of 
registration allows for a great deal of user error due to the limitation of the human 





5.1.3 IMRT Analysis Profiles 
After applying the calibration curve to the scanned film, and registering the 
TPS dose image and the film, RIT can perform the automated IMRT QA analysis.  
The software is programmed to compare the two images on a pixel by pixel basis 
using different criterion for different profiles.  For example, the Van Dyk criterion 
is used for histograms or any of the gradient profiles comparing the patient 
exposure to the TPS calculated exposure pixel by pixel [16].   
Horizontal and vertical profiles are typically used in IMRT QA analysis to 
detect any spatial discrepancies between the calculated and measured dose 
distribution.  After registering the images, this analysis plots a line profile spatially 
corresponding to either a horizontal or vertical line in both images (Figure19).  
For each profile there will be two lines, a solid line and a dashed line.  One line 
corresponds to the film (measured) dose distribution image, and the other line 
corresponds to the TPS (calculated) dose distribution image.  If the images are 
registered properly and the QA was accurately delivered, the two lines should 
virtually overlap.  Due to small errors in MLC movement, QA set-up, and 
registration, the lines may not be identical, but should be extremely similar in 
shape.  The horizontal and vertical profile lines can be moved in both images to 
spatially evaluate different areas of the dose distribution.   
Besides horizontal and vertical profiles, the gamma function is one of the 
most widely used analysis profiles due to its ability to analyze high gradient 
regions of the dose distribution.  The gamma function combines a dose 
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difference measurement with a distance to agreement (DTA) measurement to 
assign a numerical value to each pixel in the distribution. A gamma value greater 
than one indicates a failure of both measurements, and the pixel appears red in 
color.  The dose difference measurement is a user specified tolerance dependent 
on the calculated dose from the TPS.  For example, if the TPS calculated a pixel 
value to be 10 cGy and the dose difference tolerance was set to +/- 3%, the 
software would search the measured (film) pixel values until it found a pixel 
between 9.7 cGy and 10.3 cGy.  The DTA measurement is the distance between 
a measured pixel (film) and the nearest calculated pixel (TPS) that contains the 
same dose value.  For this part of the gamma analysis, the user defines a 
maximum search area (in mm) where the calculations are to be performed.  
Adding onto the above example for the dose difference measurement, the 
software is now constrained to a specific search radius.  If the DTA criterion was 
set to 3mm, the software would look for another pixel that was between 9.7 cGy 
and 10.3 cGy, and was 3mm or less in distance from the original pixel.  At TCSC, 
we use a 3% dose tolerance and a 3mm distance to agreement as our gamma 
criteria.   
The calculation of gamma throughout the measured dose distribution 
provides a visual analysis that quantitatively indicates the delivery accuracy 
relative to the acceptance tolerances, and is displayed as a Gamma Pass/Fail 
plot.  This type of analysis is based on a technique created by Lowe et al of the 
Mallinckrodt Institute [17-19].   
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5.2 Rando Phantom Results 
A study performed by Thomas et al published in “Medical Physics” 
recently reported the results of IMRT verifications for ten patients planned and 
treated with helical Tomotherapy. This study reported that nearly 92% of the film 
pixels within the analyzed region of interest were within a gamma criterion of 2 
mm and 2% [20].   Like most Tomotherapy users, Thomas et al used a test 
phantom made of homogeneous water equivalent material which could have 
masked potential errors that arise from limitations in the treatment planning 
system’s modeling of density corrections.  This study evaluated the dosimetric 
accuracy of a helical tomotherapy system using an anthropomorphic RANDO 
phantom for patient-specific QA.  The results of this study allowed a benchmark 
to be established for dosimetric accuracy in heterogeneous materials.   
A 3mm DTA and 3% dose difference tolerance were used as the gamma 
analysis criteria for the RANDO phantom study.  The results using the RANDO 
phantom were in stark contrast to those of Thomas et al.  The mean gamma 
index value and the percent of pixels exceeding the gamma threshold for the 
RANDO phantom study are shown in Table I.  Upon examination of Table I, it is 
apparent that the calculated and measured dose distributions for the prostate test 
cases had a better agreement than the lung cases.  On average, the lung 
patients had 27.2% of the pixels exceeding gamma, and the prostate patients 
had 14.7% of the pixels exceeding gamma.  For the prostate test cases, only two 
of the films had greater than 20% of the pixels exceed the gamma threshold.  In 
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contrast, sixteen of the lung test cases had pixels that exceeded the gamma 
threshold.     
A close investigation of the calculated versus measured dose distributions 
for the 24 test patients provides insight into the source of these differences.  The 
gamma pass/fail plots for the lung cases are shown in Figures 20-31, and the 
prostate cases are shown in Figures 32-43.  For the lung cases, the greatest 
discrepancy between calculated and measured dose occurred at or near a 
drastic change in tissue density.  A discrepancy is defined as a pixel that fails to 
meet the gamma criteria.  Discrepancies appeared at the tumor-low density lung 
tissue interface as well as the tumor-bone interface.  All the lung cases except 
numbers 4, 8, 9, and 12 had pixels that exceeded that gamma threshold limit of 
20%.  The sixteen patients who did not meet the 20% gamma threshold limit had 
tumor volumes that were near one of the above mentioned interfaces.  These 
discrepancy regions were also high-gradient dose regions located near the edge 
of the tumor volume.  This area is known as the penumbra region where the dose 
rapidly changes as a function of distance from the beam axis.   
Despite the prostate calculated and measure dose distributions having 
better agreement, the same trend identified in the lung cases was apparent in the 
prostate gamma pass/fail analysis plots.  The prostate cases had virtually no 
discrepancies at the tumor-tissue interface.  This is most likely due to the fact 
that the prostate itself is soft tissue and is surrounded by soft tissue in the pelvis; 
therefore there is not change in tissue density.  The prostate cases had the 
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greatest discrepancy at or near the tumor-bone interfaces in the pelvis (pubic 
symphasis and ischial tuberoscities).  Further inspection of the prostate cases 
showed that prostate cases 2, 3, 8, and 11 displayed the greatest discrepancy in 
the gamma analysis.  The pixels that failed the gamma criteria were located 
mainly at or near the pubic symphasis.  The pubic symphasis is commonly 
referred to as the pubic bone, and is located at the top of the prostate.  The 
horizontal and vertical profiles for all the RANDO test cases are shown in Figures 
44-67.  The profiles indicate that for the majority of the test cases the dose 
distributions were spatially correct.  Lung cases 3 and 11 and prostate case 3 
seemed to have the greatest discrepancy spatially with the vertical profile.  All 
RANDO test case dose distributions were spatially aligned horizontally.   
Because the RANDO phantom contains both bone and soft tissue, it is not 
surprising that the results of the IMRT QA analysis in this study are different from 
those obtained using homogenous phantoms.  At the bone-tissue interface 
(prostate and pubic symphasis), there is a greater amount of electron backscatter 
as the beam interacts with the bone causing a slight dose enhancement in the 
tissue adjacent to the bone, which is limited to a few millimeters [4, 21-27].  On 
the transmission side of the tissue-bone interface, there is a slight forward scatter 
of electrons from the bone.  This forward scatter can cause a build-up of 
electrons in the soft tissue giving rise to a dose perturbation.  In contrast to 
published results, it is a possibility that the backscatter effect could be causing 
the gamma deficiencies due to the fact that previous tests only simulated 
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heterogeneous phantoms and were not true RANDO phantoms.  Previous 
reports used make-shift phantoms of balsa wood and different density materials 
to simulate a heterogeneous phantom.  Unlike the RANDO phantom, these 
phantoms did not have real human skeleton, lung cavities, or water equivalent 
material to represent human soft tissue.  At low energies like that of 
Tomotherapy, The American Association of Physicists in Medicine Task Group 
65 reported that these dose enhancements should not cause great change in the 
dose distribution [21].   
Many reports have revealed that incorrect doses can be computed within 
or near a low-density medium such as the lung, particularly when the field size is 
small [28-32].  In the lung where there is a tumor-low density lung tissue 
interface, Kornelson and Young state that there is a loss of lateral electronic 
equilibrium when a high energy photon beam traverses the lung due to the face 
that an increasing number of electrons travel outside the geometrical limits of the 
beam.  This causes a loss of dose on the beam axis and results in a less sharp 
dose distribution profile.  Kornelson and Young state this is only for small field 
sizes (<6x6cm2) and for energies above 6MV [33].  Epps et al suggests that a 
decrease in dose occurs at the surface beyond the cavity for large cavities such 
as the lung and small field sizes [34, 35].  Both of these reports used 
homogeneous phantoms and did not take into account contributions from tissue-
bone interfaces.  Since the RANDO phantom QA plans were designed so that 
the tumor resided inside the phantom in the same anatomical site as in the 
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patient, some tumors were located at or near a tissue-bone interface.  Taking into 
account the electron scatter effect at the tumor edge and possible backscatter 
effects from tissue-bone interfaces, introduces a possible cause as to why lung 
cases 1, 2, 5, 6, and 11 failed to meet the gamma criteria.   
While it is clear that the heterogeneities have an effect on the measured 
dose distributions, it is unclear if these errors are due to film response at the 
tissue-bone interfaces or from actual dose calculation errors [21-38].  In order to 
rule out set-up error as a cause of the above mentioned discrepancies, the 
reproducibility of the film dosimetry was tested for two prostate and two lung 
cases.  Repeat measurements were taken on three separate occasions, and the 
films were processed on separate days from one another (Figure 68).  The 
standard deviation for the number of pixels exceeding the gamma threshold was 
3.9%.  For the prostate cases, the spatial location of the dose errors was not 
consistent between measurements as shown in repeat measurement two.  In 
contrast, the spatial location of the maximum error for the lung cases was 
consistent from measurement to measurement.  Because the prostate 
measurements were not consistent, set-up errors could not be ruled out as a 
possible cause of the discrepancies.   
 
5.3 MatriXX Detector Results 
The primary objective of this portion of the study was to determine if the 
MatriXX detector could be used as a substitute for radiographic film in rotational 
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IMRT delivery techniques, such as Tomotherapy.  In order to be useful for these 
delivery techniques, the device must be angular independent in dose-response 
and be capable of measuring composite dose distributions created during 
rotation.  A total of twenty helical tomotherapy test cases have been measured 
and evaluated (12 prostates, 3 head & neck, 2 paraspinal metastasis, 1 brain 
tumor, 1 esophageal tumor, and 1 mesothelioma).  This group of patients 
represented a broad spectrum of patients treated with rotational modulated 
delivery.   
After analyzing and comparing the gamma pass/fail plots for EDR2 film 
and the  MatriXX detector, it was shown that the EDR2 film had a much better 
agreement between calculated and measured dose distributions than the 
MatriXX data (Figures 69-88).  From the gamma analysis, the percent of pixels 
exceeding the threshold with a 3% dose difference tolerance and 3-mm DTA 
criteria was 10.8 ± 6.7% for the EDR film verses 23.4 ± 13.8% for the MatriXX as 
shown in Table II.  For the EDR film, test case 14 was the only case to have 
more than 20% of the pixels exceed the gamma threshold.  In contrast, half of 
the MatriXX test cases exceeded the gamma threshold by more than 20%.  
While some test cases had large discrepancies between calculated and 
measured dose distributions in both the film and the MatriXX data (Patients 2, 11, 
and 14), the patient with the worst agreement using the MatriXX (Patient 8) 
appeared normal in the film analysis. 
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Further investigating the tumor volume size and the MatriXX 
specifications, it was determined that the MatriXX appears to function well in 
high-dose low-gradient regions and low-dose low-gradient regions.  The gamma 
pass/fail plots confirmed the MatriXX has difficulty in regions with steep dose 
gradients, such as the penumbra region at the edge of the tumor volume.  This is 
likely due to a combination of two issues.  The first issue is the fact that the 
MatriXX performs volume averaging across the 4.5 x 5 mm2 chambers.  The size 
of the ion chambers used in the MatriXX seem small, but are actually quite large 
in reference to tumor size and high-gradient regions.  Because of this, errors 
seem to be intensified.  The second issue is the coarse 7.62 mm center-to-center 
spacing of the chambers.  In rotational IMRT delivery, the dose gradients are 
frequently 5-10% per mm.  Given the geometry and spacing of the individual 
detectors, the dose can easily be out of tolerance in the gamma calculations [39, 
40].  In this study, the MatriXX was set to interpolate the measured doses to a 3 
mm resolution during data acquisition.  Even with the interpolation between the 
measured data points, it was very difficult to meet the 3-mm spatial DTA criteria 
for the gamma pass/fail plots. 
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6.1 RANDO Phantom 
The RANDO phantom study evaluated the dosimetric accuracy of a helical 
tomotherapy system using an anthropomorphic RANDO phantom for patient-
specific QA.  The results of this study allowed a benchmark to be established for 
dosimetric accuracy in heterogeneous materials.  Using a 3mm DTA and 3% 
dose difference tolerance, 12 prostate and 12 lung test cases were analyzed.  
The results using the RANDO phantom were in stark contrast to those of 
homogeneous phantom studies, especially for the lung test cases.  While it is 
clear that the heterogeneities of the RANDO phantom have an effect on the 
measured dose distributions, it is unclear if these errors are due to film response 
at the tissue-bone interfaces or from actual dose calculation errors.  As shown 
from the repeat measurements, set-up error can not be ruled out as a possible 
contributor to the analysis discrepancies.  The size, weight, and inefficient set-up 
do not make the RANDO phantom a good modality for IMRT QA at the present 
time.  More investigation is needed before this becomes a routine modality for 





6.2 Matrixx Detector 
The primary objective of the MatriXX study was to determine if the 
MatriXX detector could be used as a substitute for radiographic film in rotational 
IMRT delivery techniques, such as Tomotherapy.  A total of twenty helical 
tomotherapy test cases were analyzed using a 3mm DTA and 3% dose 
difference tolerance.  The results showed that the MatriXX appears to function 
well in high-dose low-gradient regions and low-dose low-gradient regions.  The 
gamma pass/fail plots confirmed the MatriXX has difficulty in regions with steep 
dose gradients due to volume averaging and the coarse 7.62 mm center-to-
center spacing of the chambers.  Because of this, the dose can be out of 
tolerance considering the dose gradients are frequently 5-10% per mm for 
rotational IMRT.  Based on the analysis of the MatriXX data, half of the patients 
in this study would not have passed our institution’s patient-specific IMRT QA 
testing.  In contrast, only one patient would not have passed for measurements 
taken with film.  The MatriXX is limited in its spatial resolution and has difficulty 
adequately verifying plans with steep dose gradients. At this time, the MatriXX 
may not be the best modality for rotational IMRT delivery techniques.  Further 
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Figure 1: The external components of a traditional clinical linear 




























Figure 5: Gantry head components below the bending magnet for an 



































Figure 8: Tomotherapy’s binary MLC is shown in picture A.  Picture B 
shows the resultant delivery dose pattern around a patient as 
Tomotherapy’s binary multi-leaf collimator rotates simultaneously with the 












Figure 9: When quality assurance is performed in radiation therapy and film 
is used as the dosimeter, a coronal, sagittal, or transverse plane is chosen 










Figure 10: Solid water phantoms used in quality assurance tests, solid 






Figure 11: A thimble ionization chamber commonly used in radiation 











Figure 12:  The MatriXX detector from IBA Dosimetry used for IMRT quality 







   
 
  
Figure 13: The male Alderson RANDO phantom representing a 5'9", 163 lb 












Figure 14: A 2.5 cm slice of the lung portion of the RANDO phantom.  The 
lung portion is made with a lower density material simulating human lungs 










Figure 15: The Pelvic and Lung phantoms used in the RANDO phantom 
study.  The pelvic section consisted of slices 26-35, and the lung section 


























Figure 17: The Vidar 16 Dosimetry Pro at the Thompson Cancer Survival 








    




Figure 19: Vertical and Horizontal profiles used to spatially compare the 
calculated and measure dose distributions.  If dose distributions are in 




Figure 20: Gamma Pass/Fail diagram for RANDO Lung patient 1 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 




Figure 21: Gamma Pass/Fail diagram for RANDO Lung patient 2 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 





Figure 22: Gamma Pass/Fail diagram for RANDO Lung patient 3 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 




Figure 23: Gamma Pass/Fail diagram for RANDO Lung patient 4 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 




Figure 24: Gamma Pass/Fail diagram for RANDO Lung patient 5 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 




Figure 25: Gamma Pass/Fail diagram for RANDO Lung patient 6 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 






Figure 26: Gamma Pass/Fail diagram for RANDO Lung patient 7 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 




Figure 27: Gamma Pass/Fail diagram for RANDO Lung patient 8 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 







Figure 28: Gamma Pass/Fail diagram for RANDO Lung patient 9 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 




Figure 29: Gamma Pass/Fail diagram for RANDO Lung patient 10 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 






Figure 30: Gamma Pass/Fail diagram for RANDO Lung patient 11 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 




Figure 31: Gamma Pass/Fail diagram for RANDO Lung patient 12 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 





Figure 32: Gamma Pass/Fail diagram for RANDO Prostate patient 1 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 
defined as the area of film receiving over 30% of the prescribed dose. 
 
Figure 33: Gamma Pass/Fail diagram for RANDO Prostate patient 2 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 




Figure 34: Gamma Pass/Fail diagram for RANDO Prostate patient 3 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 
defined as the area of film receiving over 30% of the prescribed dose. 
 
 
Figure 35: Gamma Pass/Fail diagram for RANDO Prostate patient 4 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 





Figure 36: Gamma Pass/Fail diagram for RANDO Prostate patient 5 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 
defined as the area of film receiving over 30% of the prescribed dose. 
 
 
Figure 37: Gamma Pass/Fail diagram for RANDO Prostate patient 6 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 




Figure 38: Gamma Pass/Fail diagram for RANDO Prostate patient 7 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 
defined as the area of film receiving over 30% of the prescribed dose. 
 
Figure 39: Gamma Pass/Fail diagram for RANDO Prostate patient 8 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 




Figure 40: Gamma Pass/Fail diagram for RANDO Prostate patient 9 using a 
3mm DTA and 3% dose difference tolerance.  The analysis region was 




Figure 41: Gamma Pass/Fail diagram for RANDO Prostate patient 10 using 
a 3mm DTA and 3% dose difference tolerance.  The analysis region was 




Figure 42: Gamma Pass/Fail diagram for RANDO Prostate patient 11 using 
a 3mm DTA and 3% dose difference tolerance.  The analysis region was 
defined as the area of film receiving over 30% of the prescribed dose. 
 
 
Figure 43: Gamma Pass/Fail diagram for RANDO Prostate patient 12 using 
a 3mm DTA and 3% dose difference tolerance.  The analysis region was 







Figure 44: Horizontal and Vertical profiles for RANDO lung patient 1.  
Horizontal and vertical profiles spatially evaluate the dose distribution 











Figure 45: Horizontal and Vertical profiles for RANDO lung patient 2.  
Horizontal and vertical profiles spatially evaluate the dose distribution 










Figure 46: Horizontal and Vertical profiles for RANDO lung patient 3.  
Horizontal and vertical profiles spatially evaluate the dose distribution 









         
        
 
Figure 47: Horizontal and Vertical profiles for RANDO lung patient 4.  
Horizontal and vertical profiles spatially evaluate the dose distribution 







                         
Figure 48: Horizontal and Vertical profiles for RANDO lung patient 5.  
Horizontal and vertical profiles spatially evaluate the dose distribution 






Figure 49: Horizontal and Vertical profiles for RANDO lung patient 6.  
Horizontal and vertical profiles spatially evaluate the dose distribution 








      
Figure 50: Horizontal and Vertical profiles for RANDO lung patient 7.  
Horizontal and vertical profiles spatially evaluate the dose distribution 









Figure 51:  Horizontal and Vertical profiles for RANDO lung patient 8.  
Horizontal and vertical profiles spatially evaluate the dose distribution 









Figure 52: Horizontal and Vertical profiles for RANDO lung patient 9.  
Horizontal and vertical profiles spatially evaluate the dose distribution 







Figure 53: Horizontal and Vertical profiles for RANDO lung patient 10.  
Horizontal and vertical profiles spatially evaluate the dose distribution 




         
Figure 54: Horizontal and Vertical profiles for RANDO lung patient 11.  
Horizontal and vertical profiles spatially evaluate the dose distribution 





                    
Figure 55: Horizontal and Vertical profiles for RANDO lung patient 12.  
Horizontal and vertical profiles spatially evaluate the dose distribution 






                  
 
Figure 56: Horizontal and Vertical profiles for RANDO prostate patient 1.  
Horizontal and vertical profiles spatially evaluate the dose distribution 








Figure 57: Horizontal and Vertical profiles for RANDO prostate patient 2.  
Horizontal and vertical profiles spatially evaluate the dose distribution 








                       
Figure 58: Horizontal and Vertical profiles for RANDO prostate patient 3.  
Horizontal and vertical profiles spatially evaluate the dose distribution 






                 
Figure 59: Horizontal and Vertical profiles for RANDO prostate patient 4.  
Horizontal and vertical profiles spatially evaluate the dose distribution 







      
Figure 60: Horizontal and Vertical profiles for RANDO prostate patient 5.  
Horizontal and vertical profiles spatially evaluate the dose distribution 






                     
Figure 61: Horizontal and Vertical profiles for RANDO prostate patient 6.  
Horizontal and vertical profiles spatially evaluate the dose distribution 




               
Figure 62: Horizontal and Vertical profiles for RANDO prostate patient 7.  
Horizontal and vertical profiles spatially evaluate the dose distribution 







                
Figure 63: Horizontal and Vertical profiles for RANDO prostate patient 8.  
Horizontal and vertical profiles spatially evaluate the dose distribution 








               
Figure 64: Horizontal and Vertical profiles for RANDO prostate patient 9.  
Horizontal and vertical profiles spatially evaluate the dose distribution 








Figure 65: Horizontal and Vertical profiles for RANDO prostate patient 10.  
Horizontal and vertical profiles spatially evaluate the dose distribution 







               
Figure 66: Horizontal and Vertical profiles for RANDO prostate patient 11.  
Horizontal and vertical profiles spatially evaluate the dose distribution 







Figure 67: Horizontal and Vertical profiles for RANDO prostate patient 12.  
Horizontal and vertical profiles spatially evaluate the dose distribution 
















Figure 68: Repeat measurements for one prostate and one lung patient 










Figure 69: Gamma Pass/Fail diagram for MatriXX study patient 1 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 






Figure 70: Gamma Pass/Fail diagram for MatriXX study patient 2 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 




                              
Figure 71: Gamma Pass/Fail diagram for MatriXX study patient 3 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 







Figure 72: Gamma Pass/Fail diagram for MatriXX study patient 4 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 








Figure 73: Gamma Pass/Fail diagram for MatriXX study patient 5 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 







Figure 74: Gamma Pass/Fail diagram for MatriXX study patient 6 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 








Figure 75: Gamma Pass/Fail diagram for MatriXX study patient 7 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 











Figure 76: Gamma Pass/Fail diagram for MatriXX study patient 8 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 








Figure 77: Gamma Pass/Fail diagram for MatriXX study patient 9 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 






Figure 78: Gamma Pass/Fail diagram for MatriXX study patient 10 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 









Figure 79: Gamma Pass/Fail diagram for MatriXX study patient 11 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested is 
Kodak EDR2 film.  The analysis region was defined as the area of film 








Figure 80: Gamma Pass/Fail diagram for MatriXX study patient 12 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 




Figure 81: Gamma Pass/Fail diagram for MatriXX study patient 13 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 







Figure 82: Gamma Pass/Fail diagram for MatriXX study patient 14 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 




Figure 83: Gamma Pass/Fail diagram for MatriXX study patient 15 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 




Figure 84: Gamma Pass/Fail diagram for MatriXX study patient 16 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 







Figure 85: Gamma Pass/Fail diagram for MatriXX study patient 17 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 









Figure 86: Gamma Pass/Fail diagram for MatriXX study patient 18 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 







Figure 87: Gamma Pass/Fail diagram for MatriXX study patient 19 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 








Figure 88: Gamma Pass/Fail diagram for MatriXX study patient 20 using a 
3mm DTA and 3% dose difference tolerance.  The modality being tested in 
the top image is Kodak EDR2 film.  The modality being tested in the bottom 






























Table 1 : The mean gamma index and the percent of pixels exceeding the 
gamma threshold with analysis criteria of 3mm DTA and 3% dose 





Mean Gamma  
Index 
Percent Exceeding  
Gamma 
1 0.55 6% 
2 0.61 18% 
3 0.62 14% 
4 0.67 18% 
5 0.65 19% 
6 0.69 20% 
7 0.55 9% 
8 0.72 24% 
9 0.57 8% 
10 0.55 10% 
11 0.74 23% 
12 0.50 5% 
Prostate Test Cases 
Patient  
Number  
Mean Gamma  
Index 
Percent Exceeding  
Gamma 
1 0.82 30% 
2 0.79 31% 
3 0.71 23% 
4 0.63 13% 
5 1.13 49% 
6 0.87 29% 
7 0.82 30% 
8 0.55 10% 
9 0.64 16% 
10 0.77 27% 
11 4.57 55% 
12 0.59 12% 




Table 2: The percent of pixels exceeding the gamma threshold with 
analysis criteria of 3mm DTA and 3% dose difference tolerance for the 20 










Patient Film  MatriXX 




















Average 10.8% 23.4% 
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